Carmen D. Zorrilla to Adult
This is a "connection" page, showing publications Carmen D. Zorrilla has written about Adult.
Connection Strength
0.563
-
Zorrilla CD, Rodr?guez-Figueroa L, Miranda-De Le?n S, L?pez-Alvarado B, P?rez E, Rabionet SE. Elimination of the Perinatal Transmission of HIV and Syphilis in Puerto Rico and Sustained Success since 2007: Convergence of Science, Women-Centered Care, and Policy. P R Health Sci J. 2021 03; 40(1):12-18.
Score: 0.064
-
Lebov JF, Arias JF, Balmaseda A, Britt W, Cordero JF, Galv?o LA, Garces AL, Hambidge KM, Harris E, Ko A, Krebs N, Marques ETA, Martinez AM, McClure E, Miranda-Filho DB, Moreira MEL, Mussi-Pinhata MM, Ochoa TJ, Osorio JE, Scalabrin DMF, Schultz-Cherry S, Seage GR, Stolka K, Ugarte-Gil CA, Vega CMV, Welton M, Ximenes R, Zorrilla C. International prospective observational cohort study of Zika in infants and pregnancy (ZIP study): study protocol. BMC Pregnancy Childbirth. 2019 Aug 07; 19(1):282.
Score: 0.058
-
Col?n-L?pez V, Ortiz AP, P?rez N, Acevedo E, Tamayo V, Zorrilla CD. Measuring Knowledge of Cancer Screening and Prevention Strategies in HIV Healthcare Professionals. P R Health Sci J. 2016 09; 35(3):147-53.
Score: 0.047
-
Silva-Su?rez G, Bastida E, Rabionet SE, Beck-Sagu? C, Febo I, Zorrilla CD. "That's True Love:" Lived Experiences of Puerto Rican Perinatally HIV-Infected Youth within Their Families' Context. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010007.
Score: 0.045
-
Jim?ez J, Morales M, Castro E, Puig M, V?lez CN, Santiago L, Zorrilla C. Levels of felt stigma among a group of people with HIV in Puerto Rico. P R Health Sci J. 2012 Jun; 31(2):64-70.
Score: 0.035
-
Jimenez JC, Puig M, Ramos JC, Morales M, Asencio G, Sala AC, Castro E, Velez Santori C, Santiago L, Zorrilla C. Measuring HIV felt stigma: a culturally adapted scale targeting PLWHA in Puerto Rico. AIDS Care. 2010 Nov; 22(11):1314-22.
Score: 0.031
-
Weinberg A, Muresan P, Richardson K, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ. Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women. AIDS Res Hum Retroviruses. 2015 Nov; 31(11):1170-7.
Score: 0.022
-
Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sep; 16(8):502-11.
Score: 0.021
-
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012 Jul 15; 206(2):258-66.
Score: 0.017
-
Haas DW, Cramer YS, Godfrey C, Rosenkranz SL, Aweeka F, Berzins B, Coombs R, Coughlin K, Moran LE, Gingrich D, Zorrilla CD, Baker P, Cohn SE, Scarsi KK. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. Pharmacogenet Genomics. 2020 04; 30(3):45-53.
Score: 0.015
-
Scarsi KK, Cramer YS, Rosenkranz SL, Aweeka F, Berzins B, Coombs RW, Coughlin K, Moran LE, Zorrilla CD, Akelo V, Aziz M, Friedman RK, Gingrich D, Swaminathan S, Godfrey C, Cohn SE. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. Lancet HIV. 2019 09; 6(9):e601-e612.
Score: 0.014
-
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008 Nov 29; 372(9653):1881-1893.
Score: 0.014
-
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008 Oct 02; 359(14):1429-41.
Score: 0.014
-
F?tkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008 Oct 02; 359(14):1442-55.
Score: 0.014
-
Carballo-Di?guez A, Giguere R, Dolezal C, Leu CS, Bal?n IC, Brown W, Rael C, Richardson BA, Piper JM, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla CD, Lama JR, McGowan I, Cranston RD. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men. AIDS Behav. 2017 Dec; 21(12):3336-3345.
Score: 0.013
-
Carballo-Di?guez A, Bal?n IC, Brown W, Giguere R, Dolezal C, Leu CS, Marzinke MA, Hendrix CW, Piper JM, Richardson BA, Grossman C, Johnson S, Gomez K, Horn S, Kunjara Na Ayudhya RP, Patterson K, Jacobson C, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla C, Lama J, McGowan I, Cranston RD. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS One. 2017; 12(7):e0181607.
Score: 0.012
-
Cranston RD, Lama JR, Richardson BA, Carballo-Di?guez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu CS, Galaska B, Jacobson CE, Parikh UM, Marzinke MA, Hendrix CW, Johnson S, Piper JM, Grossman C, Ho KS, Lucas J, Pickett J, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu AY, Mayer KH, Zorrilla C, Schwartz JL, Rooney J, McGowan I. MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clin Infect Dis. 2017 03 01; 64(5):614-620.
Score: 0.012
-
Ramgopal M, Osiyemi O, Zorrilla C, Crauwels HM, Ryan R, Brown K, Hillewaert V, Baugh B. Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women. J Acquir Immune Defic Syndr. 2016 11 01; 73(3):268-274.
Score: 0.012
-
Deschamps MM, Zorrilla CD, Morgan CA, Donastorg Y, Metch B, Madenwald T, Joseph P, Severe K, Garced S, Perez M, Escamilia G, Swann E, Pape JW. Recruitment of Caribbean female commercial sex workers at high risk of HIV infection. Rev Panam Salud Publica. 2013 Aug; 34(2):92-8.
Score: 0.009
-
Eley T, Huang SP, Conradie F, Zorrilla CD, Josipovic D, Botes M, Osiyemi O, Hardy H, Bertz R, McGrath D. Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy. AIDS Res Hum Retroviruses. 2013 Oct; 29(10):1287-92.
Score: 0.009
-
Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16; 378(9787):229-37.
Score: 0.008
-
Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010 Sep 21; 153(6):349-57.
Score: 0.008
-
Djomand G, Metch B, Zorrilla CD, Donastorg Y, Casapia M, Villafana T, Pape J, Figueroa P, Hansen M, Buchbinder S, Beyrer C. The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2008 May 01; 48(1):82-9.
Score: 0.007
-
Chen KT, Tuomala RE, Chu C, Huang ML, Watts DH, Zorrilla CD, Paul M, Hershow R, Larussa P. No association between antepartum serologic and genital tract evidence of herpes simplex virus-2 coinfection and perinatal HIV-1 transmission. Am J Obstet Gynecol. 2008 Apr; 198(4):399.e1-5.
Score: 0.006
-
Torres R, Hilerio CM, Silva G, Ortiz NY, Zorrilla CD, Santiago LE. Concerns about HIV and sexually transmitted infection among low-risk and high-risk women, Puerto Rico. Ethn Dis. 2008; 18(2 Suppl 2):S2-238-41.
Score: 0.006
-
Minkoff H, Shen X, Xian LS, Watts DH, Leighty R, Hershow R, Palefsky J, Tuomala R, Neu N, Zorrilla CD, Paul M, Strickler H. Relationship of pregnancy to human papillomavirus among human immunodeficiency virus-infected women. Obstet Gynecol. 2006 Oct; 108(4):953-60.
Score: 0.006
-
Wojna V, Skolasky RL, Hechavarr?a R, Mayo R, Selnes O, McArthur JC, Mel?ndez LM, Maldonado E, Zorrilla CD, Garc?a H, Kraiselburd E, Nath A. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol. 2006 Oct; 12(5):356-64.
Score: 0.006
-
Navas-Nacher EL, Read JS, Leighty RM, Tuomala RE, Zorrilla CD, Landesman S, Rosenblatt H, Hershow RC. Mode of delivery and postpartum HIV-1 disease progression: the Women and Infants Transmission Study. AIDS. 2006 Feb 14; 20(3):429-36.
Score: 0.006
-
Morris AB, Dobles AR, Cu-Uvin S, Zorrilla C, Anderson J, Harwell JI, Keller J, Garb J. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr. 2005 Sep 01; 40(1):30-3.
Score: 0.005
-
Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, Landesman S, Zorrilla C, Thompson B. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005 Apr 01; 38(4):449-73.
Score: 0.005
-
Hilerio CM, Mart?nez J, Zorrilla CD, Torres R. Posttraumatic stress disorder symptoms and adherence among women living with HIV. Ethn Dis. 2005; 15(4 Suppl 5):S5-47-50.
Score: 0.005
-
Charurat M, Blattner W, Hershow R, Buck A, Zorrilla CD, Watts DH, Paul M, Landesman S, Adeniyi-Jones S, Tuomala R. Changing trends in clinical AIDS presentations and survival among HIV-1-infected women. J Womens Health (Larchmt). 2004 Jul-Aug; 13(6):719-30.
Score: 0.005
-
Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, Pompeo L, Stek AM, Pitt J, Watts DH, Smith E, Jim?nez E, Mofenson L. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004 Feb; 48(2):430-6.
Score: 0.005
-
Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R, Pitt J, Zorrilla CD, Hammill H, Adeniyi-Jones SK, Thompson B. The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol. 2003 Aug; 189(2):552-9.
Score: 0.005